|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Total knee arthroplasty in patients 55 years old or younger:,10 to 17 years result显示文摘 | Duffy GP Trousdale BT Stuart MJ | 1998 | Clin Orthop Relat Res1998，，356： | 1 |
| 2 | Urokinase plasminogen activator:a prognostic marker in breast cancer including patients with axillary node-negative disease显示文摘 | Duffy MJ Duggan C Mulcahy HE | 1998 | Clin Chem1998，44，61： | 1 |
| 3 | Survivin:a promising tumor biomarker显示文摘 | Duffy MJ O'Donovan N Brennan DJ | 2007 | CancerLett2007，249，1： | 1 |
| 4 | The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer 显示文摘 | Duffy MJ Duggan C | 2004 | Clin Biochem2004，37，7： | 1 |
| 5 | Protease as prognostic markers in cancer显示文摘 | Duffy MJ | 1996 | Clin Cancer Res1996，2，4： | 1 |
| 6 | National Academy ofClinical Biochemistry Laboratory Medicine Practice Guidelines foruse of tumor markers in liver, bladder, cervical, and gastric cancers显示文摘 | Sturgeon CM Duffy MJ Hofmann BR | 2010 | Clin Chem2010，56，6： | 1 |
| 7 | National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric canc- ers显示文摘 | Sturgeon CM Duffy MJ Hofmann BR | 2010 | Clin Chem2010，56，6： | 1 |
| 8 | Survivin: A new target for anti- cancer therapy 显示文摘 | Ryan BM Donovan N Duffy MJ | 2009 | Cancer Treat Rev2009，35，7： | 1 |
| 9 | Serum tumor markers in breast cancer: are they of clinical value 显示文摘 | Duffy MJ | 2006 | Clin Chem2006，52，3： | 1 |
| 10 | Nephro-urological complications of epidermolysis bullosa in paediatric patients显示文摘 | CHAN SM DILLON MJ DUFFY PG | 2007 | Br J Dermatol2007，156，： | 1 |
| 11 | Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update显示文摘 | MJ Duffy R Lamerz C Haglund | 2014 | International Journal of Cancer2014，134，11： | 1 |
| 12 | Cancer metastasis: biological and clinical aspects 显示文摘 | Duffy MJ | 1998 | J Med Sci1998，167，1： | 1 |
| 13 | The pH and titratable acidity of intravenous infusion solutions显示文摘 | Duffy C Bookallil MJ | 1972 | Anaesth Intensive Care1972，1，1： | 1 |
| 14 | Proteases as prognostic markers in cancer显示文摘 | Duffy MJ | 1996 | Clin Cancer Res1996，2，4： | 1 |
| 15 | Urokinase plasminogen activator:a prognostic marker in breast cancer including patients with axillary node-negative disease显示文摘 | Duffy MJ Duggan C Mulcahy HE | 1998 | Clin Chem1998，44，61： | 1 |
| 16 | Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury显示文摘 | Craig TR Duffy MJ Shyamsundar M | 2010 | Crit Care Med2010，38，1： | 1 |
| 17 | The urokinase plasminogen activator system: arich source of tumour markers for the individualised management ofpatients with cancer显示文摘 | Duffy MJ Duggan C | 2004 | Clin Biochem2004，37，7： | 1 |
| 18 | HER-2 signaling and inhi- bition in breast cancer显示文摘 | Browne BC OBrien N Duffy MJ | 2009 | Curt Cancer Drug Targets2009，9，3： | 1 |
| 19 | Use of molecular markers for predicting therapy response in cancer patients 显示文摘 | Duffy MJ O^onovan N Crown J | 2011 | Cancer Treat Rev2011，37，2： | 1 |
| 20 | Urokinase plasminogen activator and its inhibitor,PAI-1,as prognostic markers in breast cancer from pilot to level 1 evidence studies显示文摘 | Duffy MJ | 2002 | Clin Chem2002，48，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员